Adocia (BATS-CHIXE:ADOCP) - Stock Price, News & Analysis

ADOCP Stock Overview

A clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases.

About the company

ADOCP fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Rewards

Trading at 91.1% below our estimate of its fair value

Revenue is forecast to grow 73.97% per year

Risk Analysis

Earnings have declined by 14.4% per year over past 5 years

Negative shareholders equity

Shareholders have been substantially diluted in the past year

Shares are highly illiquid

Adocia SA Competitors

Bioventix

AIM:BVXP

UK£206.2m

Tissue Regenix Group

AIM:TRX

UK£39.2m

Avacta Group

AIM:AVCT

UK£177.6m

Arecor Therapeutics

AIM:AREC

UK£25.5m

Price History & Performance

Summary of all time highs, changes and price drops for Adocia
Historical stock prices
Current Share Price	€7.82
52 Week High	€10.16
52 Week Low	€7.82
Beta	0.83
11 Month Change	0%
3 Month Change	n/a
1 Year Change	133.43%
33 Year Change	-5.33%
5 Year Change	-43.90%
Change since IPO	22.38%

Recent updates

Shareholder Returns

	ADOCP	GB Biotechs	GB Market
7D	0%	0.8%	0.03%
1Y	133.4%	-19.1%	7.4%

Return vs Industry: ADOCP exceeded the UK Biotechs industry which returned -26.7% over the past year.

Return vs Market: ADOCP exceeded the UK Market which returned -6.5% over the past year.

Price Volatility

Is ADOCP's price volatile compared to industry and market?
ADOCP volatility
ADOCP Average Weekly Movement	n/a
Biotechs Industry Average Movement	7.0%
Market Average Movement	4.6%
10% most volatile stocks in GB Market	9.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: ADOCP has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine ADOCP's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2005	97	Olivier Soula	www.adocia.com

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company’s clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide.

Adocia SA Fundamentals Summary

How do Adocia's earnings and revenue compare to its market cap?
ADOCP fundamental statistics
Market cap	€145.02m
Earnings (TTM)	-€20.54m
Revenue (TTM)	€10.84m

13.4x

P/S Ratio

-7.1x

P/E Ratio

Is ADOCP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ADOCP income statement (TTM)
Revenue	€10.84m
Cost of Revenue	€25.30m
Gross Profit	-€14.46m
Other Expenses	€6.09m
Earnings	-€20.54m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

Feb 27, 2024

Earnings per share (EPS)	-1.46
Gross Margin	-133.32%
Net Profit Margin	-189.46%
Debt/Equity Ratio	-119.7%

How did ADOCP perform over the long term?

See historical performance and comparison

Adocia BATS-CHIXE:ADOCP Stock Report